A REAL-WORLD PHARMACOVIGILANCE STUDY OF SACUBITRIL\VALSARTAN IN OLDER PEOPLE Authors: Zheng Kuai, Yu Hu Published: 2024 ABSTRACT AbstractBackgroundSacubitril\valsartan is the first-in-class angiotensin receptor neprilysin inhibitor which is utilized clinically in the treatment of heart failure with reduced ejection fraction and hypertension patients. However, Systematic studies of sacubitril\valsartan-related adverse events (AEs) signals in older people based on real-world and international databases are still lacking. MethodsDisproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi- item gamma Poisson shrinker (MGPS) algorithms, were employed to quantify the signals of Sacubitril\valsartan-associated AEs in older people. ResultsThe search retrieved 94,210 sacubitril\valsartan-associated cases within the reporting period; 86 PTs with significant disproportionality were retained in 65+. Angioedema, hypotension, renal impairment, hyperkalemia, cough, dizziness, and seasonal allergies were found at a similar rate to those reported in trials. Reports emerged for several cognitive-related AEs and several fragility acceleration AEs, which were rare. Unexpected safety signals such as ‘Injury, poisoning, and procedural complications’ were only detected in 65+. Most of the cases occurred within the first month after sacubitril\valsartan initiation, and this was consistent across age groups. ConclusionsOur study found potential new AEs signals and might provide important support for clinical monitoring and risk identification of Sacubitril\valsartan in older people.